AbbVie Stock | ABBV | US00287Y1091 | A1J84E | July 2025

Date	AbbVie Price
7/3/2025	0 undefined
7/2/2025	191.02 undefined
7/2/2025	190.76 undefined
7/1/2025	190.51 undefined
6/30/2025	185.39 undefined
6/27/2025	183.01 undefined
6/27/2025	182.31 undefined
6/26/2025	186.39 undefined
6/25/2025	185.40 undefined
6/24/2025	185.71 undefined
6/23/2025	183.77 undefined
6/20/2025	184.51 undefined
6/18/2025	185.01 undefined
6/18/2025	185.50 undefined
6/17/2025	185.49 undefined
6/16/2025	190.87 undefined
6/13/2025	191.09 undefined
6/12/2025	192.04 undefined
6/11/2025	191.51 undefined
6/10/2025	189.01 undefined
6/9/2025	190.85 undefined
6/6/2025	189.84 undefined
6/5/2025	187.48 undefined
6/4/2025	187.35 undefined
6/3/2025	188.01 undefined

Date	AbbVie Revenue	AbbVie EBIT	AbbVie Net Income
2030e	79.89 B undefined	0 undefined	33.54 B undefined
2029e	78.54 B undefined	40.56 B undefined	33.07 B undefined
2028e	75.07 B undefined	37.92 B undefined	30.55 B undefined
2027e	70.75 B undefined	35.5 B undefined	28.06 B undefined
2026e	66.12 B undefined	32.15 B undefined	25.37 B undefined
2025e	61.11 B undefined	28.52 B undefined	22.15 B undefined
2024	56.33 B undefined	16.5 B undefined	4.24 B undefined
2023	54.32 B undefined	16.55 B undefined	4.82 B undefined
2022	58.05 B undefined	20.12 B undefined	11.78 B undefined
2021	56.2 B undefined	19.47 B undefined	11.47 B undefined
2020	45.8 B undefined	13.07 B undefined	4.56 B undefined
2019	33.27 B undefined	13.32 B undefined	7.84 B undefined
2018	32.75 B undefined	12.07 B undefined	5.66 B undefined
2017	28.22 B undefined	9.8 B undefined	5.28 B undefined
2016	25.64 B undefined	9.6 B undefined	5.92 B undefined
2015	22.86 B undefined	7.87 B undefined	5.14 B undefined
2014	19.96 B undefined	3.76 B undefined	1.77 B undefined
2013	18.79 B undefined	6.02 B undefined	4.13 B undefined
2012	18.38 B undefined	6.3 B undefined	5.28 B undefined
2011	17.44 B undefined	4.5 B undefined	3.43 B undefined
2010	15.64 B undefined	5.18 B undefined	4.18 B undefined
2009	14.21 B undefined	5.13 B undefined	4.64 B undefined

	Revenue	EBIT	Net Income
2009	14.21 B USD	5.13 B USD	4.64 B USD
2010	15.64 B USD	5.18 B USD	4.18 B USD
2011	17.44 B USD	4.5 B USD	3.43 B USD
2012	18.38 B USD	6.3 B USD	5.28 B USD
2013	18.79 B USD	6.02 B USD	4.13 B USD
2014	19.96 B USD	3.76 B USD	1.77 B USD
2015	22.86 B USD	7.87 B USD	5.14 B USD
2016	25.64 B USD	9.6 B USD	5.92 B USD
2017	28.22 B USD	9.8 B USD	5.28 B USD
2018	32.75 B USD	12.07 B USD	5.66 B USD
2019	33.27 B USD	13.32 B USD	7.84 B USD
2020	45.8 B USD	13.07 B USD	4.56 B USD
2021	56.2 B USD	19.47 B USD	11.47 B USD
2022	58.05 B USD	20.12 B USD	11.78 B USD
2023	54.32 B USD	16.55 B USD	4.82 B USD
2024	56.33 B USD	16.5 B USD	4.24 B USD
2025e	61.11 B USD	28.52 B USD	22.15 B USD
2026e	66.12 B USD	32.15 B USD	25.37 B USD
2027e	70.75 B USD	35.5 B USD	28.06 B USD
2028e	75.07 B USD	37.92 B USD	30.55 B USD
2029e	78.54 B USD	40.56 B USD	33.07 B USD
2030e	79.89 B USD	0 USD	33.54 B USD

2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024

0.01	0.65	7.98	9.9	8.37	8.41	6.42	9.79	8.06	39.92	8.48	9.83	9.23	12.82	5.56
3.37	3.82	4.3	3.85	3.74	4.73	4.76	5.09	5.38	5.43	8.82	9.98	11.25	11.16	10.92
0	0	0	949	0	0	0	0	0	0	0	0	0	0	0
0.84	0.87	1.09	1.15	1.12	1.72	1.44	1.61	1.61	1.81	3.31	3.13	3.58	4.1	4.18
4	2.01	1.99	2	2.85	1.46	3.56	4.74	1.9	2.35	3.56	4.99	4.4	4.93	4.93
8.22	7.35	15.35	17.85	16.08	16.31	16.19	21.22	16.95	49.52	24.17	27.93	28.46	33	25.58
2.36	2.14	2.25	2.3	2.49	2.57	2.6	2.8	2.88	3.31	6.14	5.87	5.67	5.73	5.86
0.14	0.23	0.12	0.12	0.09	0.15	1.78	2.09	1.42	0.09	0.29	0.28	0.24	0.3	0.28
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3.69	2.91	2.32	1.89	1.51	19.71	28.9	27.56	21.23	18.65	82.88	75.95	67.44	55.61	60.07
6.2	6.1	6.13	6.28	5.86	13.17	15.42	15.79	15.66	15.6	33.12	32.38	32.16	32.29	34.96
0.53	0.78	0.84	0.77	1.48	1.15	1.21	1.33	1.21	1.94	3.96	4.12	4.83	7.77	8.42
12.92	12.17	11.65	11.35	11.43	36.74	49.91	49.56	42.41	39.6	126.39	118.6	110.34	101.71	109.58
21.13	19.52	27.01	29.2	27.51	53.05	66.1	70.79	59.35	89.12	150.57	146.53	138.81	134.71	135.16

0	0	0	16	16	17	18	18	18	18	18	18	18	18	18
0	0	0	3.67	4.19	13.08	13.68	14.27	14.76	15.19	17.38	18.31	19.25	20.18	21.33
0	0	0	1.57	0.54	2.25	4.38	5.46	3.37	4.72	1.06	3.13	4.78	-1	-7.9
15.7	11.91	3.36	-0.44	-2.03	-2.61	-2.63	-2.73	-2.47	-3.6	-3.12	-2.9	-2.2	-2.31	-1.93
0	26	0	2	0	47	46	0	-10	0	0	0	0	0	0
15.7	11.93	3.36	4.81	2.71	12.78	15.49	17.02	15.66	16.33	15.34	18.55	21.85	16.89	11.53
0.36	3.91	5.73	6.38	6.89	4.53	4.78	5.1	5.57	4.58	8.79	9.94	9	10.32	9.95
3.4	1.97	0	0	0	2.99	3.53	3.83	4.73	5.42	9.03	10.22	12.25	15.6	16.47
0	0	0	0.07	0.06	0.95	1.07	1.29	1.63	1.83	2.34	2.54	4.15	4.74	5.53
0	0	1.02	0.41	0.43	0.41	0.38	0.4	3.7	0	0.03	0.01	0	0	0
0	0.02	0.02	0.02	4.01	2.03	0.03	6.02	1.61	3.75	8.47	12.48	4.14	7.19	6.8
3.76	5.9	6.78	6.88	11.39	10.89	9.78	16.64	17.24	15.59	28.66	35.19	29.54	37.84	38.75
0	0.03	14.63	14.29	10.54	29.24	36.44	30.95	35	62.98	77.55	64.19	59.14	52.19	60.34
0	0	0	0	0.16	5.28	6.89	2.49	1.07	1.13	3.65	3.01	2.19	1.95	2.58
1.67	1.66	2.24	3.54	3.68	3.7	8.35	15.61	14.49	17.6	27.61	28.7	30.66	32.33	30.13
1.67	1.69	16.87	17.83	14.38	38.21	51.68	49.05	50.56	81.7	108.81	95.9	91.98	86.47	93.05
5.43	7.59	23.65	24.71	25.77	49.11	61.46	65.69	67.8	97.29	137.47	131.09	121.52	124.31	131.8
21.13	19.52	27.01	29.52	28.49	61.89	76.95	82.71	83.46	113.62	152.81	149.64	143.37	141.21	143.32

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
4.64	4.18	3.43	5.28	4.13	1.77	5.14	5.95	5.31	5.69	7.88	4.62	11.55	11.85	4.87
0.7	1.18	1.27	1.15	0.9	0.79	0.84	1.19	1.5	1.77	2.02	6.47	8.52	8.47	8.7
0	0	0	0	0	0	0	0	0	0	0	-2,325	-898	-1,931	-2,889
0.5	-0.87	0.71	-0.62	0.66	-0.79	0.5	-1.69	0.01	-1.13	-1.33	0.11	-1.32	-0.26	2.81
-0.31	0.65	1	0.73	0.8	2.02	1.33	1.94	3.51	7.52	5.18	9.47	5.62	7.49	10.09
0	0	0	0	0.28	0.42	0.54	0.99	1.1	1.22	1.79	2.62	2.71	2.55	2.47
0	0	0	0	1.31	0.5	1.11	3.56	1.7	0.04	1.45	1.67	3.65	2.99	4.7
5.37	4.98	6.25	6.35	6.27	3.55	7.54	7.04	9.96	13.43	13.32	17.59	22.78	24.94	22.84
-312	-448	-355	-333	-491	-612	-532	-479	-529	-638	-552	-798	-787	-695	-777
-486	-5,031	553	-2,418	879	-926	-12,936	-6,074	-274	-1,006	596	-37,557	-2,344	-623	-2,009
-0.17	-4.58	0.91	-2.09	1.37	-0.31	-12.4	-5.6	0.26	-0.37	1.15	-36.76	-1.56	0.07	-1.23
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-0.03	-0.03	-0.02	15.59	-0.6	0.01	16.62	5.59	-0	3.23	26.25	-2.68	-8.41	-12.43	-4.15
0	0	0	0	27	-427	-7,425	-5,765	-1,156	-11,941	-621	-769	-690	-1,225	-1,792
-4.88	0.07	-6.78	1.93	-3.44	-3.29	5.75	-3.93	-5.51	-14.4	18.71	-11.5	-19.04	-24.8	-17.22
-4,846	97	-6,761	-13,655	-313	-217	-152	-34	-246	-104	-552	-333	-674	-1,102	-742
0	0	0	0	-2,555	-2,661	-3,294	-3,717	-4,107	-5,580	-6,366	-7,716	-9,261	-10,043	-10,539
0	0.01	0.02	5.87	3.69	-1.25	0.05	-3.3	4.2	-2.01	32.64	-31.48	1.3	-0.55	3.61
5,054.77	4,528.02	5,891.45	6,012	5,776	2,937	7,003	6,562	9,431	12,789	12,772	16,790	21,990	24,248	22,062
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

AbbVie Gross margin	AbbVie Profit margin	AbbVie EBIT margin	AbbVie Profit margin
2030e	69.99 %	0 %	41.99 %
2029e	69.99 %	51.65 %	42.11 %
2028e	69.99 %	50.52 %	40.69 %
2027e	69.99 %	50.18 %	39.66 %
2026e	69.99 %	48.63 %	38.36 %
2025e	69.99 %	46.66 %	36.25 %
2024	69.99 %	29.28 %	7.52 %
2023	66.45 %	30.47 %	8.87 %
2022	71.53 %	34.66 %	20.29 %
2021	69.19 %	34.65 %	20.41 %
2020	66.69 %	28.53 %	9.95 %
2019	77.14 %	40.04 %	23.57 %
2018	76.93 %	36.85 %	17.27 %
2017	74.63 %	34.74 %	18.72 %
2016	77.32 %	37.46 %	23.1 %
2015	80.31 %	34.43 %	22.5 %
2014	77.83 %	18.85 %	8.89 %
2013	75.62 %	32.02 %	21.97 %
2012	75.47 %	34.28 %	28.7 %
2011	73.64 %	25.79 %	19.68 %
2010	72.59 %	33.11 %	26.72 %
2009	71.46 %	36.08 %	32.62 %

	Gross margin	EBIT margin	Profit margin
2009	71.46 %	36.08 %	32.62 %
2010	72.59 %	33.11 %	26.72 %
2011	73.64 %	25.79 %	19.68 %
2012	75.47 %	34.28 %	28.7 %
2013	75.62 %	32.02 %	21.97 %
2014	77.83 %	18.85 %	8.89 %
2015	80.31 %	34.43 %	22.5 %
2016	77.32 %	37.46 %	23.1 %
2017	74.63 %	34.74 %	18.72 %
2018	76.93 %	36.85 %	17.27 %
2019	77.14 %	40.04 %	23.57 %
2020	66.69 %	28.53 %	9.95 %
2021	69.19 %	34.65 %	20.41 %
2022	71.53 %	34.66 %	20.29 %
2023	66.45 %	30.47 %	8.87 %
2024	69.99 %	29.28 %	7.52 %
2025e	69.99 %	46.66 %	36.25 %
2026e	69.99 %	48.63 %	38.36 %
2027e	69.99 %	50.18 %	39.66 %
2028e	69.99 %	50.52 %	40.69 %
2029e	69.99 %	51.65 %	42.11 %
2030e	69.99 %	0 %	41.99 %

Date	AbbVie Sales per Share	AbbVie EBIT per share	AbbVie Earnings per Share
2030e	45.06 undefined	0 undefined	18.92 undefined
2029e	44.3 undefined	0 undefined	18.65 undefined
2028e	42.34 undefined	0 undefined	17.23 undefined
2027e	39.9 undefined	0 undefined	15.82 undefined
2026e	37.29 undefined	0 undefined	14.31 undefined
2025e	34.47 undefined	0 undefined	12.49 undefined
2024	31.77 undefined	9.3 undefined	2.39 undefined
2023	30.64 undefined	9.34 undefined	2.72 undefined
2022	32.65 undefined	11.32 undefined	6.63 undefined
2021	31.62 undefined	10.96 undefined	6.45 undefined
2020	27.38 undefined	7.81 undefined	2.72 undefined
2019	22.42 undefined	8.98 undefined	5.28 undefined
2018	21.19 undefined	7.81 undefined	3.66 undefined
2017	17.6 undefined	6.11 undefined	3.3 undefined
2016	15.72 undefined	5.89 undefined	3.63 undefined
2015	13.96 undefined	4.81 undefined	3.14 undefined
2014	12.4 undefined	2.34 undefined	1.1 undefined
2013	11.71 undefined	3.75 undefined	2.57 undefined
2012	11.66 undefined	4 undefined	3.34 undefined
2011	11.04 undefined	2.85 undefined	2.17 undefined
2010	9.89 undefined	3.27 undefined	2.64 undefined
2009	8.99 undefined	3.24 undefined	2.93 undefined

	Sales per Share	EBIT per share	Earnings per Share
2009	8.99 USD	3.24 USD	2.93 USD
2010	9.89 USD	3.27 USD	2.64 USD
2011	11.04 USD	2.85 USD	2.17 USD
2012	11.66 USD	4 USD	3.34 USD
2013	11.71 USD	3.75 USD	2.57 USD
2014	12.4 USD	2.34 USD	1.1 USD
2015	13.96 USD	4.81 USD	3.14 USD
2016	15.72 USD	5.89 USD	3.63 USD
2017	17.6 USD	6.11 USD	3.3 USD
2018	21.19 USD	7.81 USD	3.66 USD
2019	22.42 USD	8.98 USD	5.28 USD
2020	27.38 USD	7.81 USD	2.72 USD
2021	31.62 USD	10.96 USD	6.45 USD
2022	32.65 USD	11.32 USD	6.63 USD
2023	30.64 USD	9.34 USD	2.72 USD
2024	31.77 USD	9.3 USD	2.39 USD
2025e	34.47 USD	0 USD	12.49 USD
2026e	37.29 USD	0 USD	14.31 USD
2027e	39.9 USD	0 USD	15.82 USD
2028e	42.34 USD	0 USD	17.23 USD
2029e	44.3 USD	0 USD	18.65 USD
2030e	45.06 USD	0 USD	18.92 USD

Segmente	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Humira	21.24 B USD	-	-	-	-	-	-	-	-	-
Skyrizi	-	2.94 B USD	1.59 B USD	-	-	-	-	-	-	-
SKYRIZI	-	-	-	355 M USD	-	-	-	-	-	-

	Humira	Skyrizi	SKYRIZI
2013	0 USD	0 USD	0 USD
2014	0 USD	0 USD	0 USD
2015	0 USD	0 USD	0 USD
2016	0 USD	0 USD	0 USD
2017	0 USD	0 USD	0 USD
2018	0 USD	0 USD	0 USD
2019	0 USD	0 USD	355 M USD
2020	0 USD	1.59 B USD	0 USD
2021	0 USD	2.94 B USD	0 USD
2022	21.24 B USD	0 USD	0 USD

Segmente	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
HUMIRA	-	-	-	19.17 B USD	-	18.43 B USD	16.08 B USD	-	-	10.66 B USD
Humira	-	20.69 B USD	19.83 B USD	-	-	-	-	-	-	-
Represents information pertaining to HUMIRA, a product of the entity	-	-	-	-	-	-	-	14.01 B USD	12.54 B USD	-
All other	4.14 B USD	-	2.92 B USD	511 M USD	319 M USD	998 M USD	1.22 B USD	-	-	-
Imbruvica	4.57 B USD	-	5.31 B USD	-	-	-	-	-	-	-
IMBRUVICA	-	-	-	4.67 B USD	-	2.57 B USD	1.83 B USD	-	-	-
Creon	1.28 B USD	-	1.11 B USD	1.04 B USD	-	831 M USD	730 M USD	-	-	412 M USD
Skyrizi	5.17 B USD	-	-	-	-	-	-	-	-	-
Botox Therapeutic	2.72 B USD	-	1.39 B USD	-	-	-	-	-	-	-
Lupron	-	-	752 M USD	887 M USD	-	829 M USD	821 M USD	-	-	785 M USD
Botox Cosmetic	2.62 B USD	-	1.11 B USD	-	-	-	-	-	-	-
Synthroid	-	-	771 M USD	786 M USD	-	781 M USD	763 M USD	-	-	622 M USD
Mavyret	1.54 B USD	-	1.83 B USD	-	-	-	-	-	-	-
Venclexta	2.01 B USD	-	1.34 B USD	-	-	-	-	-	-	-
Rinvoq	2.52 B USD	-	731 M USD	-	-	-	-	-	-	-
Synagis	-	-	-	718 M USD	-	738 M USD	730 M USD	-	-	827 M USD
Vraylar	2.04 B USD	-	951 M USD	-	-	-	-	-	-	-
MAVYRET	-	-	-	2.89 B USD	-	-	-	-	-	-
Represents information pertaining to other products of the entity not specified anywhere	-	-	-	-	-	-	-	1.22 B USD	1.63 B USD	-
Represents information pertaining to AndroGel, a product of the entity	-	-	-	-	-	-	-	694 M USD	934 M USD	1.04 B USD
Represents information pertaining to Kaletra, a product of the entity	-	-	-	-	-	-	-	700 M USD	870 M USD	962 M USD
Duodopa	458 M USD	-	494 M USD	461 M USD	-	355 M USD	293 M USD	-	-	178 M USD
Juvederm Collection	1.43 B USD	-	718 M USD	-	-	-	-	-	-	-
Other Aesthetics	1.29 B USD	-	760 M USD	-	-	-	-	-	-	-
Other Eye Care	1.18 B USD	-	693 M USD	-	-	-	-	-	-	-
Sevoflurane	-	-	-	348 M USD	-	410 M USD	428 M USD	-	-	568 M USD
Linzess/Constella	1.04 B USD	-	667 M USD	-	-	-	-	-	-	-
Represents information pertaining to VIEKIRA, a product of the entity	-	-	-	-	-	-	-	1.64 B USD	48 M USD	-
Other Products	-	-	-	-	-	-	-	-	-	1.67 B USD
Represents information pertaining to Lupron, a product of the entity	-	-	-	-	-	-	-	826 M USD	778 M USD	-
Represents information pertaining to Synagis, a product of the entity	-	-	-	-	-	-	-	740 M USD	835 M USD	-
VIEKIRA	-	-	-	36 M USD	-	-	1.52 B USD	-	-	-
Represents information pertaining to Synthroid, a product of the entity	-	-	-	-	-	-	-	755 M USD	709 M USD	-
Restasis	666 M USD	-	787 M USD	-	-	-	-	-	-	-
AndroGel	-	-	-	172 M USD	-	577 M USD	675 M USD	-	-	-
HCV	-	-	-	-	-	1.27 B USD	-	-	-	-
Kaletra	-	-	-	283 M USD	-	423 M USD	549 M USD	-	-	-
Represents information pertaining to Creon, a product of the entity	-	-	-	-	-	-	-	632 M USD	516 M USD	-
Dyslipidemia Products	-	-	-	-	-	-	-	-	-	1.08 B USD
Represents information pertaining to Sevoflurane, a product of the entity	-	-	-	-	-	-	-	474 M USD	550 M USD	-
Other Neuroscience	475 M USD	-	539 M USD	-	-	-	-	-	-	-
Lumigan/Ganfort	514 M USD	-	378 M USD	-	-	-	-	-	-	-
Ubrelvy	680 M USD	-	125 M USD	-	-	-	-	-	-	-
VENCLEXTA	-	-	-	792 M USD	-	-	-	-	-	-
Represents information pertaining to Imbruvica, a product of the entity	-	-	-	-	-	-	-	754 M USD	-	-
Alphagan/Combigan	346 M USD	-	326 M USD	-	-	-	-	-	-	-
Represents information pertaining to dyslipidemia products of the entity	-	-	-	-	-	-	-	179 M USD	328 M USD	-
Represents information pertaining to Duodopa, a product of the entity	-	-	-	-	-	-	-	231 M USD	220 M USD	-
Lo Loestrin	-	-	356 M USD	-	-	-	-	-	-	-
Other Women's Health	-	-	192 M USD	-	-	-	-	-	-	-
Qulipta	158 M USD	-	-	-	-	-	-	-	-	-
Orilissa/Oriahnn	-	-	125 M USD	-	-	-	-	-	-	-
ORILISSA	-	-	-	93 M USD	-	-	-	-	-	-
RINVOQ	-	-	-	47 M USD	-	-	-	-	-	-

Segmente	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Imbruvica	-	5.41 B USD	-	-	-	-	-	-	-	-
All other	-	2.67 B USD	-	-	-	-	-	-	-	-
Botox Therapeutic	-	2.45 B USD	-	-	-	-	-	-	-	-
Botox Cosmetic	-	2.23 B USD	-	-	-	-	-	-	-	-
Venclexta	-	1.82 B USD	-	-	-	-	-	-	-	-
Vraylar	-	1.73 B USD	-	-	-	-	-	-	-	-
Mavyret	-	1.71 B USD	-	-	-	-	-	-	-	-
Rinvoq	-	1.65 B USD	-	-	-	-	-	-	-	-
Juvederm Collection	-	1.54 B USD	-	-	-	-	-	-	-	-
Other Aesthetics	-	1.47 B USD	-	-	-	-	-	-	-	-
Restasis	-	1.29 B USD	-	-	-	-	-	-	-	-
Creon	-	1.19 B USD	-	-	-	-	-	-	-	-
Other Eye Care	-	1.17 B USD	-	-	-	-	-	-	-	-
Linzess/Constella	-	1.04 B USD	-	-	-	-	-	-	-	-
Lupron	-	783 M USD	-	-	-	-	-	-	-	-
Synthroid	-	767 M USD	-	-	-	-	-	-	-	-
Other Neuroscience	-	685 M USD	-	-	-	-	-	-	-	-
Lumigan/Ganfort	-	579 M USD	-	-	-	-	-	-	-	-
Ubrelvy	-	552 M USD	-	-	-	-	-	-	-	-
Alphagan/Combigan	-	529 M USD	-	-	-	-	-	-	-	-
Duodopa	-	511 M USD	-	-	-	-	-	-	-	-
Lo Loestrin	-	437 M USD	-	-	-	-	-	-	-	-
Other Women's Health	-	214 M USD	-	-	-	-	-	-	-	-
Orilissa/Oriahnn	-	145 M USD	-	-	-	-	-	-	-	-

	Number of stocks
2009	1.58 B Aktien
2010	1.58 B Aktien
2011	1.58 B Aktien
2012	1.58 B Aktien
2013	1.6 B Aktien
2014	1.61 B Aktien
2015	1.64 B Aktien
2016	1.63 B Aktien
2017	1.6 B Aktien
2018	1.55 B Aktien
2019	1.48 B Aktien
2020	1.67 B Aktien
2021	1.78 B Aktien
2022	1.78 B Aktien
2023	1.77 B Aktien
2024	1.77 B Aktien
2025e	1.77 B Aktien
2026e	1.77 B Aktien
2027e	1.77 B Aktien
2028e	1.77 B Aktien
2029e	1.77 B Aktien
2030e	1.77 B Aktien

Date	AbbVie Dividend
2030e	6.28 undefined
2029e	6.25 undefined
2028e	6.27 undefined
2027e	6.33 undefined
2026e	6.16 undefined
2025e	6.33 undefined
2024	6.2 undefined
2023	5.92 undefined
2022	5.64 undefined
2021	5.2 undefined
2020	4.72 undefined
2019	4.28 undefined
2018	3.59 undefined
2017	2.56 undefined
2016	2.28 undefined
2015	2.02 undefined
2014	1.66 undefined
2013	1.6 undefined

	Dividend	Dividend (Estimate)
2009	0 USD	0 USD
2010	0 USD	0 USD
2011	0 USD	0 USD
2012	0 USD	0 USD
2013	1.6 USD	0 USD
2014	1.66 USD	0 USD
2015	2.02 USD	0 USD
2016	2.28 USD	0 USD
2017	2.56 USD	0 USD
2018	3.59 USD	0 USD
2019	4.28 USD	0 USD
2020	4.72 USD	0 USD
2021	5.2 USD	0 USD
2022	5.64 USD	0 USD
2023	5.92 USD	0 USD
2024	6.2 USD	0 USD
2025e	0 USD	6.33 USD
2026e	0 USD	6.16 USD
2027e	0 USD	6.33 USD
2028e	0 USD	6.27 USD
2029e	0 USD	6.25 USD
2030e	0 USD	6.28 USD

Date	AbbVie Payout ratio
2030e	98.03 %
2029e	98.77 %
2028e	98.34 %
2027e	96.98 %
2026e	101 %
2025e	97.02 %
2024	92.92 %
2023	113.07 %
2022	85.07 %
2021	80.62 %
2020	173.53 %
2019	81.06 %
2018	98.36 %
2017	77.81 %
2016	62.81 %
2015	64.33 %
2014	150.91 %
2013	62.26 %
2012	113.07 %
2011	113.07 %
2010	113.07 %
2009	113.07 %

	Payout ratio
2009	113.07 %
2010	113.07 %
2011	113.07 %
2012	113.07 %
2013	62.26 %
2014	150.91 %
2015	64.33 %
2016	62.81 %
2017	77.81 %
2018	98.36 %
2019	81.06 %
2020	173.53 %
2021	80.62 %
2022	85.07 %
2023	113.07 %
2024	92.92 %
2025e	97.02 %
2026e	101 %
2027e	96.98 %
2028e	98.34 %
2029e	98.77 %
2030e	98.03 %

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2025	2.43	2.46 (1.14 %)	2025 Q1
12/31/2024	2.16	2.16 (0.02 %)	2024 Q4
9/30/2024	2.97	3 (0.9 %)	2024 Q3
6/30/2024	2.62	2.65 (1.28 %)	2024 Q2
3/31/2024	2.27	2.31 (1.73 %)	2024 Q1
12/31/2023	2.82	2.79 (-1.14 %)	2023 Q4
9/30/2023	2.91	2.95 (1.23 %)	2023 Q3
6/30/2023	2.86	2.91 (1.65 %)	2023 Q2
3/31/2023	2.51	2.46 (-1.85 %)	2023 Q1
12/31/2022	3.63	3.6 (-0.83 %)	2022 Q4
9/30/2022	3.64	3.66 (0.42 %)	2022 Q3
6/30/2022	3.38	3.37 (-0.31 %)	2022 Q2
3/31/2022	3.2	3.24 (1.11 %)	2022 Q1
12/31/2021	3.35	3.31 (-1.24 %)	2021 Q4
9/30/2021	3.29	3.33 (1.3 %)	2021 Q3
6/30/2021	3.15	3.09 (-1.96 %)	2021 Q2
3/31/2021	2.89	2.95 (2.25 %)	2021 Q1
12/31/2020	2.91	2.92 (0.42 %)	2020 Q4
9/30/2020	2.82	2.83 (0.34 %)	2020 Q3
6/30/2020	2.23	2.34 (4.8 %)	2020 Q2
3/31/2020	2.29	2.42 (5.63 %)	2020 Q1
12/31/2019	2.24	2.21 (-1.15 %)	2019 Q4
9/30/2019	2.34	2.33 (-0.54 %)	2019 Q3
6/30/2019	2.26	2.26 (0.21 %)	2019 Q2
3/31/2019	2.1	2.14 (2.14 %)	2019 Q1
12/31/2018	1.98	1.9 (-3.87 %)	2018 Q4
9/30/2018	2.06	2.14 (4.1 %)	2018 Q3
6/30/2018	2.01	2 (-0.63 %)	2018 Q2
3/31/2018	1.83	1.87 (2.25 %)	2018 Q1
12/31/2017	1.47	1.48 (0.89 %)	2017 Q4
9/30/2017	1.41	1.41 (-0.18 %)	2017 Q3
6/30/2017	1.43	1.42 (-0.46 %)	2017 Q2
3/31/2017	1.29	1.28 (-0.54 %)	2017 Q1
12/31/2016	1.22	1.2 (-1.58 %)	2016 Q4
9/30/2016	1.22	1.21 (-0.93 %)	2016 Q3
6/30/2016	1.22	1.26 (2.92 %)	2016 Q2
3/31/2016	1.16	1.15 (-0.48 %)	2016 Q1
12/31/2015	1.14	1.13 (-1.22 %)	2015 Q4
9/30/2015	1.1	1.13 (2.7 %)	2015 Q3
6/30/2015	1.08	1.08 (-0.04 %)	2015 Q2
3/31/2015	0.87	0.94 (8.05 %)	2015 Q1
12/31/2014	0.87	0.89 (1.9 %)	2014 Q4
9/30/2014	0.79	0.89 (12.93 %)	2014 Q3
6/30/2014	0.77	0.82 (6.05 %)	2014 Q2
3/31/2014	0.69	0.71 (2.36 %)	2014 Q1
12/31/2013	0.84	0.82 (-2.42 %)	2013 Q4
9/30/2013	0.79	0.82 (3.6 %)	2013 Q3
6/30/2013	0.8	0.82 (2.12 %)	2013 Q2
3/31/2013	0.68	0.68 (0.1 %)	2013 Q1

%	Name	Stocks	Change	Date
9.76581 %	The Vanguard Group, Inc.	173,147,725	842,635	3/31/2025
5.13438 %	BlackRock Institutional Trust Company, N.A.	91,032,546	950,858	3/31/2025
4.51004 %	State Street Global Advisors (US)	79,962,967	341,480	3/31/2025
2.15756 %	Geode Capital Management, L.L.C.	38,253,590	1,108,657	3/31/2025
2.00828 %	JP Morgan Asset Management	35,606,865	1,702,095	3/31/2025
1.88990 %	Capital Research Global Investors	33,508,014	-475,693	3/31/2025
1.42505 %	Charles Schwab Investment Management, Inc.	25,266,107	-2,170,026	3/31/2025
1.41540 %	Norges Bank Investment Management (NBIM)	25,095,020	2,616,555	12/31/2024
1.31150 %	Morgan Stanley Smith Barney LLC	23,252,965	571,370	3/31/2025
1.20846 %	Fidelity Management & Research Company LLC	21,426,073	4,440,848	3/31/2025
1.15830 %	Capital International Investors	20,536,730	-7,996,758	3/31/2025
0.91870 %	Managed Account Advisors LLC	16,288,617	1,963,105	3/31/2025
0.91177 %	Capital World Investors	16,165,653	-244,624	3/31/2025
0.81339 %	BlackRock Asset Management Ireland Limited	14,421,492	1,074,728	3/31/2025
0.76295 %	Northern Trust Investments, Inc.	13,527,124	-200,528	3/31/2025
0.74670 %	BlackRock Investment Management (UK) Ltd.	13,238,977	398,459	3/31/2025
0.68918 %	Columbia Threadneedle Investments (US)	12,219,159	-621,499	3/31/2025
0.65888 %	Legal & General Investment Management Ltd.	11,681,928	97,315	3/31/2025
0.65792 %	BofA Global Research (US)	11,664,913	666,460	3/31/2025
0.56207 %	UBS Financial Services, Inc.	9,965,465	-799,240	3/31/2025
0.54410 %	Parametric Portfolio Associates LLC	9,646,899	440,227	3/31/2025
0.53091 %	Dimensional Fund Advisors, L.P.	9,413,033	45,871	3/31/2025
0.52916 %	Goldman Sachs Asset Management, L.P.	9,382,056	505,114	3/31/2025
0.51441 %	Putnam Investment Management, L.L.C.	9,120,569	41,395	3/31/2025
0.48589 %	MFS Investment Management	8,614,779	-213,911	3/31/2025
0.47992 %	BlackRock Financial Management, Inc.	8,509,063	927,705	3/31/2025
0.42342 %	Nuveen LLC	7,507,182	-401,414	3/31/2025
0.41812 %	Franklin Advisers, Inc.	7,413,270	417,582	3/31/2025
0.38159 %	Wells Fargo Advisors	6,765,674	-14,911	3/31/2025
0.37510 %	State Farm Insurance Companies	6,650,459	3,200	3/31/2025
0.36431 %	Mellon Investments Corporation	6,459,146	-364,219	3/31/2025
0.35788 %	Boston Partners	6,345,296	657,824	3/31/2025
0.35087 %	JPMorgan Private Bank (United States)	6,220,855	582,626	3/31/2025
0.31977 %	California Public Employees' Retirement System	5,669,484	709,748	3/31/2025
0.30561 %	J.P. Morgan Securities LLC	5,418,468	-148,270	3/31/2025
0.29260 %	Amundi Asset Management, SAS	5,187,807	-1,756,190	3/31/2025
0.28537 %	Envestnet Asset Management, Inc.	5,059,568	95,756	3/31/2025
0.28111 %	Schweizerische Nationalbank	4,984,010	-5,800	3/31/2025
0.28007 %	BlackRock (Netherlands) B.V.	4,965,600	-109,149	3/31/2025
0.27662 %	Invesco Advisers, Inc.	4,904,511	1,447,829	3/31/2025
0.27268 %	JPMorgan Asset Management U.K. Limited	4,834,625	-164,490	3/31/2025
0.26283 %	Northern Trust Global Investments	4,659,890	33,645	3/31/2025
0.25348 %	T. Rowe Price Associates, Inc.	4,494,140	-3,043,828	3/31/2025
0.25107 %	DWS Investment GmbH	4,451,547	23,362	3/31/2025
0.25055 %	Raymond James & Associates, Inc.	4,442,192	-92,235	3/31/2025
0.24184 %	AllianceBernstein L.P.	4,287,786	-686,845	3/31/2025
0.23858 %	UBS Asset Management (Americas) LLC	4,229,961	217,639	3/31/2025
0.23145 %	Sumitomo Mitsui Trust Bank, Limited	4,103,600	-9,961	3/31/2025
0.23013 %	Nordea Funds Oy	4,080,287	1,086,553	3/31/2025
0.22664 %	BNY Mellon Asset Management	4,018,379	-65,901	3/31/2025
0.22359 %	Morgan Stanley & Co. LLC	3,964,254	961,063	3/31/2025
0.22258 %	Goldman Sachs & Company, Inc.	3,946,268	2,057,178	3/31/2025
0.21865 %	Robeco Institutional Asset Management B.V.	3,876,732	198,049	3/31/2025
0.20986 %	Janus Henderson Investors	3,720,831	-525,214	3/31/2025
0.20906 %	UBS Asset Management (UK) Ltd.	3,706,581	204,117	3/31/2025
0.20360 %	National Pension Service	3,609,835	193,296	3/31/2025
0.20120 %	HSBC Global Asset Management (UK) Limited	3,567,214	-140,548	3/31/2025
0.18964 %	PNC Investments LLC	3,362,237	6,987	3/31/2025
0.18604 %	Bahl & Gaynor, Inc.	3,298,466	-41,852	3/31/2025
0.18526 %	RBC Capital Markets Wealth Management	3,284,576	178,667	3/31/2025
0.18345 %	BlackRock Japan Co., Ltd.	3,252,589	-6,111	3/31/2025
0.18321 %	Barclays Bank PLC	3,248,363	1,165,932	3/31/2025
0.17993 %	Mitsubishi UFJ Asset Management Co., Ltd.	3,190,091	341,601	3/31/2025
0.17892 %	LPL Financial LLC	3,172,248	216,704	3/31/2025
0.17686 %	Aperio Group, LLC	3,135,729	203,960	3/31/2025
0.17609 %	UBS Asset Management (Switzerland)	3,122,157	282,368	3/31/2025
0.17497 %	Citi Investment Research (US)	3,102,304	763,274	3/31/2025
0.17365 %	American Century Investment Management, Inc.	3,078,841	-146,058	3/31/2025
0.17357 %	Invesco Capital Management LLC	3,077,464	-264,391	3/31/2025
0.17348 %	BNP Paribas Securities Corp. North America	3,075,727	1,205,059	3/31/2025
0.16981 %	Rhumbline Advisers Ltd. Partnership	3,010,690	-26,376	3/31/2025
0.16009 %	Northern Trust Global Investments Limited	2,838,436	278,499	3/31/2025
0.15807 %	BlackRock Investment Management, LLC	2,802,658	-41,122	3/31/2025
0.15670 %	California State Teachers Retirement System	2,778,274	-12,305	3/31/2025
0.15666 %	TD Asset Management Inc.	2,777,565	456,024	3/31/2025
0.15527 %	Bessemer Trust Company, N.A. (US)	2,752,953	1,641,091	3/31/2025
0.15232 %	T. Rowe Price International Ltd	2,700,674	44,416	3/31/2025
0.15106 %	Manulife Investment Management (North America) Limited	2,678,269	388,211	3/31/2025
0.15029 %	Schroder Investment Management Ltd. (SIM)	2,664,593	297,572	3/31/2025
0.14990 %	First Trust Advisors L.P.	2,657,753	-1,097,253	3/31/2025
0.14787 %	Deka Investment GmbH	2,621,797	29,149	3/31/2025
0.14752 %	Principal Global Investors (Equity)	2,615,465	149,662	3/31/2025
0.14668 %	Voya Investment Management LLC	2,600,720	499,808	3/31/2025
0.14099 %	Mackenzie Investments	2,499,736	62,437	3/31/2025
0.14075 %	DWS Investments UK Limited	2,495,471	-538,931	3/31/2025
0.13932 %	U.S. Bancorp Asset Management, Inc.	2,470,175	-38,590	3/31/2025
0.12916 %	Corient Private Wealth LLC	2,290,045	-43,870	3/31/2025
0.12472 %	New York State Common Retirement Fund	2,211,270	-12,976	3/31/2025
0.12468 %	Fidelity Institutional Asset Management	2,210,509	1,098,359	3/31/2025
0.12218 %	Fayez Sarofim & Co.	2,166,269	-39,919	3/31/2025
0.12104 %	RBC Global Asset Management Inc.	2,145,974	-20,961	3/31/2025
0.12028 %	Qube Research & Technologies Ltd	2,132,478	1,343,860	3/31/2025
0.11971 %	Ensign Peak Advisors, Inc.	2,122,416	63,027	3/31/2025
0.11511 %	Truist Bank	2,040,849	-26,505	3/31/2025
0.11276 %	Cincinnati Financial Corporation	1,999,200	0	3/31/2025
0.11128 %	Swedbank Robur Fonder AB	1,972,948	-174,178	12/31/2024
0.11089 %	ClearBridge Investments, LLC	1,966,071	-624,781	3/31/2025
0.10754 %	Boston Management and Research	1,906,682	20,695	3/31/2025
0.10637 %	Canada Life Asset Management Limited	1,885,900	-185,094	3/31/2025
0.10633 %	Stifel, Nicolaus & Company, Incorporated	1,885,152	-141,036	3/31/2025

Name	Relationship	Two-week correlation	One-month correlation	Three-Month Correlation	Six-Month Correlation	One Year Correlation	Two-Year Correlation
Asymchem Laboratories (Tianjin) H	SupplierCustomer	0,80	0,85	-0,16
Berkshire Hathaway B	SupplierCustomer	0,74	0,82	0,88	0,95	0,96	0,90
Molecular Partners AG	SupplierCustomer	0,73	0,80	0,47	0,24	-0,30
NNIT	SupplierCustomer	0,71	0,76	0,19	-0,65	-0,81	-0,68
Evolus, Inc.	SupplierCustomer	0,68	-0,26	0,28	0,85	0,34	0,55
Model N	SupplierCustomer	0,63	0,79	0,44	-0,50	-0,80	-0,77
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.	SupplierCustomer	0,62	0,65
Pfizer	SupplierCustomer	0,56	0,81	0,79	-0,28	0,60	0,81
Johnson & Johnson	SupplierCustomer	0,56	0,15	0,71	0,80	0,64	0,80
Innodata	SupplierCustomer	0,51	0,46	0,53	0,52	-0,43	0,44

What values and corporate philosophy does AbbVie represent?

Abbvie Inc represents values of innovation, integrity, and a patient-centric approach. With a corporate philosophy focused on discovering and delivering advanced solutions, Abbvie strives to make a remarkable impact on people's lives. The company is committed to advancing science and developing breakthrough treatments in various therapeutic areas, including immunology, oncology, and neuroscience. Abbvie's dedication to excellence and its emphasis on collaboration and ethical practices enable the company to provide transformative healthcare solutions for patients worldwide.

In which countries and regions is AbbVie primarily present?

Abbvie Inc is primarily present in various countries and regions worldwide. The company has a strong global presence, with a focus on key markets such as the United States, Europe, Asia Pacific, and Latin America. Abbvie Inc operates in multiple countries, including the United Kingdom, Germany, France, Italy, Japan, China, Australia, Brazil, and Mexico, among others. With their international reach, Abbvie Inc continues to expand its business operations and leverage opportunities in different markets to serve a diverse customer base.

What significant milestones has the company AbbVie achieved?

Abbvie Inc, a leading pharmaceutical company, has achieved several significant milestones. In 2013, the company was spun off from Abbott Laboratories, marking a significant step towards establishing its independent identity. Abbvie has also made remarkable progress in the development of innovative therapies. Notably, their drug Humira became a game-changer, becoming the world's best-selling medicine and achieving several regulatory approvals for multiple indications. In addition, Abbvie has expanded its pipeline with the successful launch of new products like Skyrizi and Rinvoq, further strengthening its position in the industry. These accomplishments highlight Abbvie Inc's commitment to advancing healthcare and improving patient outcomes.

What is the history and background of the company AbbVie?

Abbvie Inc is a pharmaceutical company with a rich history and background. It was established in 2013 as a spin-off from Abbott Laboratories. Abbvie focuses on researching, developing, and manufacturing innovative drugs to address various health conditions. With headquarters in North Chicago, Illinois, Abbvie operates on a global scale, delivering advanced therapies to patients worldwide. The company is renowned for its expertise in immunology, oncology, neuroscience, and virology areas. Abbvie has a diverse portfolio of products, including popular brands such as Humira, Imbruvica, and Venclexta, which have positively impacted millions of lives. With a commitment to advancing science and improving patient outcomes, Abbvie continues to make significant contributions to the healthcare industry.

Who are the main competitors of AbbVie in the market?

The main competitors of Abbvie Inc in the market include pharmaceutical companies such as Johnson & Johnson, Pfizer Inc, and Bristol-Myers Squibb Company.

In which industries is AbbVie primarily active?

Abbvie Inc is primarily active in the pharmaceutical industry.

What is the business model of AbbVie?

The business model of Abbvie Inc is focused on research, development, and commercialization of innovative pharmaceutical products. Abbvie specializes in the discovery and production of drugs primarily in the fields of immunology, oncology, and neuroscience. The company aims to provide effective therapies for various medical conditions, improving the quality of life for patients worldwide. With a strong focus on research and development, Abbvie strives to bring new treatments to market and address unmet medical needs. Through strategic partnerships and collaborations, Abbvie ensures a diversified product portfolio and maintains its position as a leading pharmaceutical company.

What is the P/E ratio of AbbVie 2025?

The P/E ratio cannot be calculated for AbbVie at the moment.

What is the P/S ratio of AbbVie 2025?

The P/S cannot be calculated for AbbVie currently.

What is the Quality Investing of AbbVie?

The Quality Investing for AbbVie is 8/10.

What is the revenue of AbbVie 2025?

The expected AbbVie revenue is 61.11 B USD.

How high is the profit of AbbVie 2025?

The expected AbbVie profit is 22.15 B USD.

What is the business model of AbbVie

Abbvie Inc. is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for some of the world's most serious diseases. This primarily includes oncology, immunological disorders, neurodegenerative diseases, skin diseases, viral and bacterial infections, eye diseases, and metabolic disorders. Abbvie has been an independent company since 2013, following a spin-off from Abbott Laboratories. The company is headquartered in North Chicago, Illinois, USA, and employs over 30,000 people worldwide. Abbvie has four main business segments: 1. Immunology: Approximately 60 percent of Abbvie's revenue comes from the immunology division. The company specializes in the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel diseases, and multiple sclerosis. Key products in the immunology division include Humira, Rinvoq, SkyRizi, and Skyrizi. 2. Hematology and Oncology: Abbvie also has a strong presence in the field of hematology and oncology. Leading products in this segment include Venclexta, Imbruvica, and Mavyret. 3. Neurology: Abbvie also offers products in the field of neurology, such as Skyrizi, Botox, Azelex, and Tazorac. 4. Aesthetic Medicine: The company offers products like Juvederm and Botox in this segment. Abbvie invests heavily in research and development to discover innovative therapies that can improve the lives of patients worldwide. The company has a strong portfolio of patents and prioritizes comprehensive clinical testing in the development of new products to ensure high quality and efficacy. Additionally, the company has formed several collaborative partnerships to accelerate its research and development in various areas. For example, Abbvie has partnered with Biogen in the development of drugs for multiple sclerosis and has cooperated with Alector in the field of neurodegenerative diseases. Abbvie continues to delight its customers with valuable products and services, thereby expanding its leading position in the biopharmaceutical industry. In summary, Abbvie is an innovative and rapidly growing company that plays an important role in the global biopharmaceutical market through its top-notch products and investments in research and development.

What is the AbbVie dividend?

AbbVie pays a dividend of 5.64 USD distributed over 4 payouts per year.

How often does AbbVie pay dividends?

AbbVie pays out a dividend 4 times a year.

What is the AbbVie ISIN?

The ISIN of AbbVie is US00287Y1091.

What is the AbbVie WKN?

The WKN of AbbVie is A1J84E.

What is the AbbVie ticker?

The ticker of AbbVie is ABBV.

How much dividend does AbbVie pay?

Over the past 12 months, AbbVie paid a dividend of 6.2 USD . This corresponds to a dividend yield of about . For the coming 12 months, AbbVie is expected to pay a dividend of 6.16 USD.

What is the dividend yield of AbbVie?

The current dividend yield of AbbVie is .

When does AbbVie pay dividends?

AbbVie pays a quarterly dividend. This is distributed in the months of November, February, May, August.

How secure is the dividend of AbbVie?

AbbVie paid dividends every year for the past 102 years.

What is the dividend of AbbVie?

For the upcoming 12 months, dividends amounting to 6.16 USD are expected. This corresponds to a dividend yield of 3.22 %.

In which sector is AbbVie located?

AbbVie is assigned to the 'Health' sector.

Wann musste ich die Aktien von AbbVie kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of AbbVie from 8/15/2025 amounting to 1.64 USD, you needed to have the stock in your portfolio before the ex-date on 7/15/2025.

When did AbbVie pay the last dividend?

The last dividend was paid out on 8/15/2025.

What was the dividend of AbbVie in the year 2024?

In the year 2024, AbbVie distributed 5.92 USD as dividends.

In which currency does AbbVie pay out the dividend?

The dividends of AbbVie are distributed in USD.

Date	All other countries	Australia	B [R]	Brazil	BRAZIL	C [A]	Canada	China	D [E]	E [S]	F [R]	France	G [B]	Germany	I [T]	Italy	J [P]	Japan	N [L]	Other Countries	Represents information pertaining to other countries not specified anywhere	Spain	The Netherlands	U [S]	United Kingdom	United States
2022	4.84 B USD	508 M USD	-	430 M USD	-	-	1.16 B USD	912 M USD	-	-	-	787 M USD	-	1.34 B USD	-	444 M USD	-	956 M USD	-	-	-	506 M USD	-	-	462 M USD	45.71 B USD
2021	4.76 B USD	533 M USD	-	368 M USD	-	-	1.4 B USD	857 M USD	-	-	-	936 M USD	-	1.22 B USD	-	506 M USD	-	1.09 B USD	-	-	-	519 M USD	-	-	497 M USD	43.51 B USD
2020	3.98 B USD	527 M USD	-	406 M USD	-	-	1.16 B USD	471 M USD	-	-	-	797 M USD	-	1.05 B USD	-	379 M USD	-	1.2 B USD	-	-	-	453 M USD	-	-	509 M USD	34.88 B USD
2019	3.99 B USD	-	-	359 M USD	-	-	813 M USD	-	-	-	-	695 M USD	-	909 M USD	-	372 M USD	-	1.21 B USD	-	-	-	472 M USD	163 M USD	-	372 M USD	23.91 B USD
2018	4.01 B USD	-	-	350 M USD	-	-	730 M USD	-	-	-	-	783 M USD	-	1.29 B USD	-	652 M USD	-	1.59 B USD	-	-	-	611 M USD	352 M USD	-	855 M USD	21.52 B USD
2017	4.08 B USD	-	-	410 M USD	-	-	659 M USD	-	-	-	-	730 M USD	-	1.16 B USD	-	475 M USD	-	764 M USD	-	-	-	521 M USD	362 M USD	-	807 M USD	18.25 B USD
2016	3.89 B USD	-	-	355 M USD	-	-	624 M USD	-	-	-	-	713 M USD	-	1.1 B USD	-	523 M USD	-	770 M USD	-	-	-	589 M USD	352 M USD	-	776 M USD	15.95 B USD
2015	-	-	376 M USD	-	-	551 M USD	-	-	1.08 B USD	618 M USD	597 M USD	-	688 M USD	-	452 M USD	-	599 M USD	-	334 M USD	-	4 B USD	-	-	13.56 B USD	-	-
2014	-	-	435 M USD	-	-	551 M USD	-	-	1.04 B USD	534 M USD	584 M USD	-	722 M USD	-	432 M USD	-	581 M USD	-	969 M USD	-	3.27 B USD	-	-	10.85 B USD	-	-
2013	-	-	-	-	439 M USD	-	538 M USD	-	-	-	-	540 M USD	-	911 M USD	-	404 M USD	-	625 M USD	-	3.15 B USD	-	543 M USD	858 M USD	-	606 M USD	10.18 B USD

Scope 1 - Direct Emissions	328,259
Scope 2 - Indirect emissions from purchased energy	237,714
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions	565,973
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Percentage of female employees	56
Percentage of women in management
Percentage of Asian employees	19
Share of Asian management	24
Percentage of Hispanic/Latino employees	10
Hispano/Latino Management share	6
Percentage of Black employees	7
Black Management Share	5
Percentage of white employees	61
White Management Share	62
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

Stock Exchange	AbbVie Ticker
DÜSSELDORF	4AB.DU
FRANKFURT	4AB.F
LONDON	0QCV.L
MILAN	1ABBV.MI
MUNICH	4AB.MU
NEW YORK	ABBV
SIX	ABBV.SW
VIENNA	ABBV.VI
XETRA	4AB.DE

2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e	2028e	2029e	2030e
14.21	15.64	17.44	18.38	18.79	19.96	22.86	25.64	28.22	32.75	33.27	45.8	56.2	58.05	54.32	56.33	61.11	66.12	70.75	75.07	78.54	79.89
-	10.02	11.55	5.37	2.23	6.23	14.52	12.16	10.06	16.08	1.57	37.69	22.69	3.30	-6.44	3.71	8.48	8.19	7.00	6.11	4.63	1.72
71.46	72.59	73.64	75.47	75.62	77.83	80.31	77.32	74.63	76.93	77.14	66.69	69.19	71.53	66.45	69.99	64.52	59.64	55.73	52.53	50.20	49.35
10.16	11.35	12.85	13.87	14.21	15.53	18.36	19.82	21.06	25.2	25.66	30.55	38.88	41.53	36.09	39.43	0	0	0	0	0	0
4.64	4.18	3.43	5.28	4.13	1.77	5.14	5.92	5.28	5.66	7.84	4.56	11.47	11.78	4.82	4.24	22.15	25.37	28.06	30.55	33.07	33.54
-	-9.90	-17.83	53.66	-21.74	-57.03	189.97	15.14	-10.81	7.08	38.62	-41.90	151.71	2.74	-59.09	-12.07	422.65	14.51	10.61	8.88	8.26	1.44
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
1.58	1.58	1.58	1.58	1.6	1.61	1.64	1.63	1.6	1.55	1.48	1.67	1.78	1.78	1.77	1.77	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

AbbVie Ticker	AbbVie FIGI
ABBV:US	BBG0025Y4RY4
ABBV:UA	BBG003P7K070
ABBV:UC	BBG003P7K089
ABBV:UN	BBG003P7K0B5
ABBV:UP	BBG003P7K0C4
ABBV:UB	BBG003P7K0F1
ABBV:UT	BBG003P7K0G0
ABBV:UM	BBG003P7K0H9
ABBV:UX	BBG003P7K0J7
ABBV:UD	BBG003P7K0Q9
ABBV:UF	BBG003P7K0T6
ABBV:VY	BBG003P7K0V3
ABBV:VJ	BBG003P7K0W2
ABBV:VK	BBG003P7K0X1
4AB:GR	BBG003Q17NN9
4AB:GF	BBG003Q17NP7
4AB:GD	BBG003Q17NQ6
4AB:GY	BBG003Q17NR5
4AB:GS	BBG003Q17NS4
4AB:GM	BBG003Q17NT3
4AB:GB	BBG003Q17NV0
ABBV:SW	BBG003S01B24
ABBV*:MM	BBG0043CS769
ABBV*:MF	BBG0043CS778
ABBVCHF:EO	BBG0058MD2K0
ABBVCHF:XH	BBG0058MD2N7
ABBVCHF:XF	BBG0058MD2Q4
ABBVCHF:XE	BBG0058MD2S2
ABBVCHF:XJ	BBG0058MD2T1
ABBVCHF:XL	BBG0058MD2V8
ABBVCHF:XG	BBG0058MD2W7
ABBVCHF:XO	BBG0058MD2X6
ABBVCHF:XS	BBG0058MD319
ABBVCHF:XA	BBG0058MD328
ABBVCHF:E1	BBG0058MD337
ABBVCHF:XT	BBG0058MD346
ABBVCHF:XW	BBG0058MD355
ABBVCHF:XU	BBG0058MD364
ABBVCHF:EU	BBG0058MD391
ABBVCHF:XV	BBG005925S34
ABBVUSD:EO	BBG005ZN1DN4
ABBVUSD:XH	BBG005ZN1DR0
ABBVUSD:XF	BBG005ZN1DT8
ABBVUSD:XE	BBG005ZN1DW4
ABBVUSD:XJ	BBG005ZN1DX3
ABBVUSD:XL	BBG005ZN1DY2
ABBVUSD:XG	BBG005ZN1DZ1
ABBVUSD:XO	BBG005ZN1F04
ABBVUSD:XS	BBG005ZN1F40
ABBVUSD:XA	BBG005ZN1F59
ABBVUSD:E1	BBG005ZN1F68
ABBVUSD:XT	BBG005ZN1F77
ABBVUSD:XW	BBG005ZN1F86
ABBVUSD:XU	BBG005ZN1F95
ABBVUSD:XV	BBG005ZN1FC1
ABBVUSD:EU	BBG005ZN1FG7
ABBV:BW	BBG006M73D22
ABBVGBP:EO	BBG006T43V95
ABBVGBP:XH	BBG006T43VD0
ABBVGBP:XF	BBG006T43VG7
ABBVGBP:XE	BBG006T43VJ4
ABBVGBP:XJ	BBG006T43VK2
ABBVGBP:XL	BBG006T43VL1
ABBVGBP:XG	BBG006T43VM0
ABBVGBP:XO	BBG006T43VN9
ABBVGBP:XS	BBG006T43VS4
ABBVGBP:XA	BBG006T43VT3
ABBVGBP:E1	BBG006T43VV0
ABBVGBP:XT	BBG006T43VW9
ABBVGBP:XW	BBG006T43VX8
ABBVGBP:XU	BBG006T43VY7
ABBVGBP:XV	BBG006T43W02
ABBVGBP:EU	BBG006T43W75
ABBVN:B3	BBG006T7TSF0
ABBVP:B3	BBG006T7TSH8
ABBVZ:B3	BBG006T7TSK4
ABBVN:L3	BBG006TC50G5
ABBVP:L3	BBG006TC50J2
ABBVZ:L3	BBG006TC50L9
ABBVEUR:EO	BBG006YGVNS8
ABBVEUR:XH	BBG006YGVNW3
ABBVEUR:XF	BBG006YGVNY1
ABBVEUR:XE	BBG006YGVP03
ABBVEUR:XJ	BBG006YGVP12
ABBVEUR:XL	BBG006YGVP21
ABBVEUR:XG	BBG006YGVP30
ABBVEUR:XO	BBG006YGVP49
ABBVEUR:XS	BBG006YGVP85
ABBVEUR:XA	BBG006YGVP94
ABBVEUR:E1	BBG006YGVPB1
ABBVEUR:XT	BBG006YGVPC0
ABBVEUR:XW	BBG006YGVPD9
ABBVEUR:XU	BBG006YGVPF7
ABBVEUR:XV	BBG006YGVPH5
ABBVEUR:EU	BBG006YGVPK1
4AB:QT	BBG0077H4M88
ABBVRUB:EO	BBG00830L460
ABBVRUB:XH	BBG00830L497
ABBVRUB:XF	BBG00830L4C3
ABBVRUB:XE	BBG00830L4F0
ABBVRUB:XJ	BBG00830L4G9
ABBVRUB:XL	BBG00830L4H8
ABBVRUB:XG	BBG00830L4J6
ABBVRUB:XO	BBG00830L4K4
ABBVRUB:XS	BBG00830L4P9
ABBVRUB:XA	BBG00830L4Q8
ABBVRUB:E1	BBG00830L4R7
ABBVRUB:XT	BBG00830L4S6
ABBVRUB:XW	BBG00830L4T5
ABBVRUB:XU	BBG00830L4V2
ABBVRUB:XV	BBG00830L4X0
ABBVRUB:EU	BBG00830L530
ABBVN:PO	BBG008GZ8NS8
ABBVP:PO	BBG008GZ8NX2
ABBVZ:PO	BBG008GZ8NZ0
4AB:TH	BBG00B3PP829
ABBV:VF	BBG00DJGV4Y5
4AB:GZ	BBG00FZMGBN2
ABBVCHF:XX	BBG00JN83D94
ABBVUSD:XX	BBG00JN85P40
ABBVGBP:XX	BBG00JN87C65
ABBVEUR:XX	BBG00JN87JB4
ABBVRUB:XX	BBG00JN8B2Q0
ABBV*:MU	BBG00JX0Q1Y3
ABBV:AV	BBG00KTDTBZ1
4ABBV:TE	BBG00LXXK9T1
ABBV:VP	BBG00X1SKHN9
ABBV-RM:RM	BBG00Y19J7H0
ABBV-RM:RX	BBG00Y19J7J8
ABBV-RM:RN	BBG00Y19J7K6
ABBV-RM:RP	BBG00Y19J7L5
ABBVN:L1	BBG00Y7B8H34
4ABD:PO	BBG0101NWK97
4ABD:L3	BBG0101NX410
4ABD:B3	BBG0101NXFD2
4ABD:L1	BBG0101NXP77
4AB:LA	BBG018H981R3
4AB:LU	BBG018J2X2K3
4AB:BU	BBG01BPF4QF5
4ABD:EB	BBG01FVKJYJ1
4ABD:IX	BBG01FVKK5R3
4ABD:I2	BBG01FVKKGH0
1ABBV:IM	BBG01K3WR5L6
1ABBV:IF	BBG01K3WR5N4

Unlimited access to the most powerful analytical tools in finance.

AbbVie Stock ABBVstock price, forecast, news, chart, split, dividend and analysis AbbVie ariva, AbbVie onvista, AbbVie finanzen.net, AbbVie aktienfinder, AbbVie marketscreener, AbbVie marketwatch, AbbVie bloomberg, AbbVie handelsblatt, AbbVie wiwo, AbbVie forum

Price

Price

TickerABBV

ISINUS00287Y1091

WKNA1J84E

AbbVie stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

AbbVie Stock Price History

AbbVie Revenue, EBIT, Net Income US00287Y1091 · A1J84E

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

AbbVie Revenue, EBIT and net profit per share

AbbVie Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

AbbVie stock margins US00287Y1091 · A1J84E

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

AbbVie Margin History

AbbVie Stock Sales Revenue, EBIT, Earnings per Share US00287Y1091 · A1J84E

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

AbbVie Revenue, EBIT and net profit per share

AbbVie business model

AbbVie SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

AbbVie Revenue by Segment US00287Y1091 · A1J84E

Revenue by Segment

Overview of Revenue by Segment

Interpretation and Use

Investment Strategy

AbbVie Revenue by Segment

Revenue by Segment

Overview of Revenue by Segment

Interpretation and Use

Investment Strategy

AbbVie Revenue by Segment

Revenue by Segment

Overview of Revenue by Segment

Interpretation and Use

Investment Strategy

AbbVie Revenue by Segment

AbbVie Revenue by Region US00287Y1091 · A1J84E

Revenue by Segment

Overview of Revenue by Region

Interpretation and Usage

Investment Strategy

AbbVie Revenue by Segment

AbbVie Stock ABBV
stock price, forecast, news, chart, split, dividend and analysis AbbVie ariva, AbbVie onvista, AbbVie finanzen.net, AbbVie aktienfinder, AbbVie marketscreener, AbbVie marketwatch, AbbVie bloomberg, AbbVie handelsblatt, AbbVie wiwo, AbbVie forum

Ticker
ABBV

ISIN
US00287Y1091

WKN
A1J84E